Polymorphism of host response genes: Implications in the pathogenesis and treatment of acute renal failure  by Jaber, Bertrand L. et al.
Kidney International, Vol. 67 (2005), pp. 14–33
PERSPECTIVES IN BASIC SCIENCE
Polymorphism of host response genes: Implications in the
pathogenesis and treatment of acute renal failure
BERTRAND L. JABER, BRIAN J.G. PEREIRA, JOSEPH V. BONVENTRE,
and VAIDYANATHAPURAM S. BALAKRISHNAN
Division of Nephrology, Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts; Division of Nephrology, Tufts-New England
Medical Center, Boston, Massachusetts; and Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts
Polymorphism of host response genes: Implications in the
pathogenesis and treatment of acute renal failure. Acute in-
flammatory disorders are the result of an interaction between
genetic and environmental factors, and are often characterized
by an imbalance between pro- and anti-inflammatory host im-
mune responses. Over the past decade, polymorphisms of host
response genes have been explored as genetic risk and prog-
nostic markers in the course and severity of acute inflammatory
disorders.
Increasing evidence supports an important role for inflam-
matory mechanisms in the pathogenesis of acute renal failure
(ARF) following both ischemic and nephrotoxic injury. The use
of genetic epidemiology may become a useful tool to identify
patients with an altered susceptibility to developing hospital-
acquired ARF, and stratify those who may benefit from pre-
ventive therapies that modulate host immune responses in a
favorable way.
This review summarizes the existing experimental and clin-
ical studies supporting the role of inflammation in ARF and
critically appraises studies that have examined polymorphism
of immune response genes as potential determinants of suscep-
tibility to and severity of acute inflammatory disorders. Conclu-
sions are drawn on the application of genetic epidemiology to
the field of ARF and the rationale for further research on the
role of genetic markers in ARF.
Acute renal failure (ARF) is a serious complication
that develops in hospitalized patients, with an incidence
of 5% to 10% [1], and case fatality rates often exceed 50%
[2]. These alarming figures have not changed in decades
despite tremendous advances in supportive and dialysis
care, and they have been ascribed in part to increasing age
and a high prevalence of comorbid conditions. ARF has
also been independently associated with increased risk of
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death following radiocontrast procedures [3] and follow-
ing cardiac surgery [4]. Interventions to prevent or im-
prove treatment of ARF are therefore urgently needed.
There is mounting evidence to support the critical role
of inflammation in the pathogenesis of ARF. This review
article is based on the premise that acute inflammatory
disorders are the result of an interaction between genetic
and environmental factors. Over the past decade, genetic
studies of common disorders have shed some light on
the relative importance of genetic risk and prognostic
markers in acute and chronic inflammatory disorders.
This review summarizes the experimental and clinical
data supporting the role of inflammation in ARF and
critically appraises studies that have examined the im-
portance of genetic markers as potential determinants of
susceptibility to and severity of acute inflammatory disor-
ders. Conclusions are drawn on the application of genetic
epidemiology to the field of ARF.
HUMAN GENETIC VARIABILITY
Although a person’s genotype represents the blending
of parental genotypes, two unrelated persons share over
99.9% of their DNA sequences [5]. Many efforts both
in the academic and commercial sector are under way
to categorize and catalog the variations observed in the
remaining 0.1% of the human genome [6]. These vari-
ants, known as gene polymorphisms, are markers of bi-
ologic diversity, and some genotypic variations correlate
with specific phenotypes relevant to human disease [7, 8].
These emerging research efforts are based on the premise
that human gene polymorphisms may be instrumental
in developing the future practice of “genomic medicine”
and individualized health care [6]. However, it is not clear
whether many of these variants are incriminated in the
pathogenesis of diseases, or are merely in proximity to
other pathogenic genetic factors, a phenomenon known
as linkage disequilibrium.
Polymorphism of human genes may be observed at one
or more of the following sites (Fig. 1): (1) the promoter
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Fig. 1. Structure of a human gene, sites of polymorphism, and functional relevance. (Modified from [205]; reprinted with permission. Jaber BL
et al: Blood Purif 22: 101–111, 2004).
or 5′-flanking region; (2) the exon(s) or the gene cod-
ing sequences; (3) the intron(s) or the gene intervening
sequences; and (4) the 3′-untranslated (3′-UTR) region.
Polymorphism involving the promoter region (5′-
flanking region) of the gene may affect transcriptional
activity and can therefore be of functional relevance
[9]. Polymorphism of the coding region or exon may be
silent or affect gene expression or function by resulting in
changes in the structure, binding or trafficking of the pro-
tein. Introns are transcribed into RNA but are cut out of
the messenger RNA (mRNA) before it is translated into
a protein molecule. Consequently, polymorphism involv-
ing the intron may lead to defects in RNA and mRNA
processing. Finally, polymorphism in the 3′-UTR region
may affect gene expression by affecting RNA half-life or
influencing ribosomal translation of mRNA [10].
TYPES OF HUMAN GENE POLYMORPHISM
Three types of human gene polymorphisms have been
described [9] (Fig. 2): (1) single nucleotide polymorphism
(SNP); (2) variable number of tandem repeats (VNTR)
or minisatellite polymorphism; and (3) microsatellite
polymorphism.
SNP is the most common class and normally consists
of single nucleotide substitution (Fig. 2A). SNP in the
promoter region of a gene may affect transcription factor
binding, transcriptional control, or other aspects of gene
expression.
Minisatellite polymorphism or VNTR results from the
insertion in tandem of multiple copies of a nucleotide se-
quence of less than 100 bp long, known as a minisatellite,
between two restriction sites (Fig. 2B). This class of poly-
morphism is characterized by many alleles, based on the
number of minisatellite copies [9].
Microsatellites are stretches of DNA in which a short
motif of one to five nucleotides is repeated several times
(Fig. 2C). A dinucleotide repeat of cytosine and adenine
(CA)n is the most commonly described form. Microsatel-
lites show heritable and stable differences among individ-
uals and are therefore polymorphic.
IDENTIFICATION OF GENES RELEVANT TO
HUMAN DISEASE
There are two approaches to identifying genes relevant
to human disease: linkage analyses and association stud-
ies. Linkage analyses identify coinheritance of a specific
phenotype with a region of the genome in families. These
analyses are successful in identifying novel genes for
“monogenic” diseases, and environmental factors tend
to play a minimal role in disease expression. One such
example is polycystic kidney disease. Association studies
identify susceptibility genes for common “polygenic” dis-
eases. This “candidate gene” approach relies on biologic
plausibility to help identify highly likely candidate genes.
In this analytical approach, gene environment interac-
tions play a critical role in disease expression. Examples
would include the study of genes encoding for cytokines
in sepsis and ARF.
We will next review host immune responses in acute in-
flammatory disorders and specifically, the inflammatory
network in ARF, with special emphasis on selected patho-
physiologic pathways incriminated in sepsis-, ischemic-,
and nephrotoxic-mediated injury.
THE HOST IMMUNE RESPONSE IN ACUTE
INFLAMMATORY STATES
During an acute inflammatory state, the host immune
response is often governed by a balance of two oppos-
ing forces, a proinflammatory response geared toward
recruitment of inflammatory cells to sites of injury and
an anti-inflammatory response aimed at limiting tissue
injury and promoting healing. These immune responses
16 Jaber et al: Gene polymorphism in acute renal failure
C
G
A
T
C
G
C
G
GC
C
G
CG
C
G
A
T
A
T
A
T
T
A
T
A
T
A
T
A
Normal
C
G
A
T
C
G
C
G
GC
C
G
CG
C
G
A
T
A
T
A
T
T
A
G
C
T
A
T
A
Substitution
A
Variable number of tandem repeats
Allele 1
Allele 2
Allele 3
Allele 4
B
ACACAC ACAC
1
1
(AC)10 (AC)18
(AC)10 (AC)14
(AC)26
(AC)18
(AC)14
(AC)10
(AC)18 (AC)26
(AC)26 (AC)14
2
2
3
3
4
4
C
Fig. 2. Types of gene polymorphism. (A) Sin-
gle nucleotide polymorphism. (B) Variable
number of tandem repeats or minisatellite loci
polymorphism (DNA sequence 10 to 100 bp in
length). (C) Microsatellite loci polymorphism
(DNA sequence of repeating units of 2 to 4
nucleotides).
are normally regulated by monocytes and lymphocytes. In
bacterial sepsis, a very common acute inflammatory state,
this balance has been termed the systemic inflammatory
response syndrome (SIRS) and the compensatory anti-
inflammatory response syndrome (CARS), and these
cellular responses are usually driven by monocytes and
neutrophils. The following is a summary of these emerg-
ing concepts.
The systemic inflammatory response syndrome (SIRS)
The SIRS is an exaggerated acute host defense re-
sponse to different triggering factors such as gram-
negative bacterial endotoxin, trauma, and burns [11]. This
leads to the release of biologically active mediators, which
activate several inflammatory cascades leading to organ
dysfunction, including ARF [12]. In the United States,
sepsis, an example of SIRS, is increasingly identified as a
common cause of morbidity and mortality, especially in
the intensive care unit setting [13].
Cytokines act in concert with specific cytokine in-
hibitors and soluble cytokine receptors to regulate the
host response. During an acute inflammatory state, stim-
uli cause monocytes to release such cytokines as tumor
necrosis factor-a (TNF-a), interleukin-1b (IL-1b) and
interleukin-6 (IL-6), which in turn cause widespread vas-
cular endothelial cell injury. Indeed, TNF-a and IL-1b
interact with the vascular endothelium, and stimulate
platelet-activating factor, prostanoids, and nitric oxide
synthesis, resulting in arterial vasodilatation, hypoten-
sion, and organ dysfunction. Furthermore, interleukin-8
(IL-8), a potent chemokine, facilitates the recruitment of
neutrophils to inflammatory sites, which in turn, release
their toxic cellular contents, including reactive oxygen
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species (ROS) and proteloytic enzymes. IL-6 also in-
duces the hepatic synthesis of positive acute-phase pro-
teins, such as C-reactive protein (CRP) and suppresses
synthesis of negative acute-phase proteins, such as albu-
min [14]. TNF-a and IL-6 also contribute to a series of
metabolic events leading to protein catabolism, a state of
negative nitrogen balance and significant loss of lean body
mass [15]. In recent years, substantial evidence has ac-
cumulated linking proinflammatory cytokines to adverse
outcomes among patients with acute inflammatory states
[16, 17].
The compensatory anti-inflammatory response
syndrome (CARS)
The CARS is believed to play a critical role in coun-
terbalancing the proinflammatory responses associated
with the SIRS. This secondary immune response is
characterized by the production of immunomodulatory
molecules that control the proinflammatory cytokine re-
sponse, thereby, counterbalancing the SIRS. Their critical
role in systemic inflammatory states is becoming recog-
nized [18]. Major anti-inflammatory monocyte-derived
molecules include IL-10, IL-1 receptor antagonist (IL-
1Ra), and soluble TNF receptors (sTNF-R).
IL-10 is the most potent anti-inflammatory cytokine,
and plays a pivotal role in the regulation of the immune
response to microbial pathogens [19]. IL-10 is released by
monocytes and inhibits production of TNF-a, IL-1b , and
IL-6 [20]. As IL-10 expression is delayed relative to that
of TNF-a, IL-1b , and IL-6, its release provides an effi-
cient autocrine mechanism for controlling proinflamma-
tory cytokine production by monocytes [21]. Although
the precise mechanisms by which IL-10 mediates these
inhibitory effects have not been determined, both tran-
scriptional and posttranscriptional mechanisms as well as
antioxidant effects have been proposed. The balance
of pro- and anti-inflammatory cascades may be impor-
tant determinants of the extent of host inflammatory
responses and adverse clinical outcomes. Knowledge
gained in the understanding of the role and regulation
of IL-10 in acute inflammatory states, for instance, may
lead to the development of therapeutic strategies aimed
at the modulation of IL-10 synthesis. Of note, the admin-
istration of glucocorticoids has been shown to modulate
the inflammatory response syndrome in favor of IL-10,
resulting in a decrease in circulating TNF-a, IL-6, and
IL-8 levels and an increase in IL-10 levels [22, 23].
The IL-1Ra is a member of the IL-1 family that binds
to IL-1 receptors but does not transduce intracellular
signals [24]. IL-1Ra is mainly secreted by monocytes in
response to other cytokines and microbial components.
Endogenous IL-1Ra is important in host defense against
endotoxin-induced injury as well as in acute and chronic
inflammatory states [25]. Studies have shown that a 1000-
fold excess of IL-1Ra is required to block the hemody-
namic effects of IL-1b [26]. Consequently, the balance
between proinflammatory cytokines such as TNF-a and
IL-1b , and their specific inhibitors such as IL-10 and
IL-1Ra, respectively, may be critical in determining the
extent of the inflammatory response, and may have an im-
portant influence on outcomes of patients suffering from
an acute inflammatory disorder.
Th1 and Th2 responses
Monocyte and T-lymphocyte interactions also play a
critical role in the systemic response to acute inflamma-
tory states. Two types of T-helper (Th) cells produce dis-
tinct patterns of cytokines. Th1 cells secrete interleukin-2
(IL-2) and interferon-gamma (IFN-c), whereas Th2 cells
mainly produce IL-4 and IL-10. The relative activation
of Th cell subsets is determined by a variety of factors,
including antigen presentation and the cytokine milieu.
In sepsis, the patterns of Th1 and Th2 cell responses are
not well known. In one study of healthy volunteers, after
low-dose endotoxin administration, the T-cell immune
response shifted toward Th2 cell type responses, with de-
pressed circulating IL-2 levels contrasting with marked
increases in IL-10 levels [27]. Although the balance of
Th1/Th2 cell activation may be important in directing
effector pathways and patterns of injury in acute glomeru-
lonephritis [28], the role of lymphocytes in the pathophys-
iology of acute tubular necrosis is less well understood.
THE INFLAMMATORY NETWORK IN ARF
Sepsis injury in ARF
ARF often develops in the setting of sepsis, and the
role of proinflammatory cytokines in the development of
endotoxin-mediated ARF is well documented [29–31].
In sepsis, cytokine release is initiated by a number of fac-
tors, including bacterial endotoxin, ischemia/reperfusion,
complement activation, and the redundant effect of other
cytokines and immune modulators (Fig. 3). This results
in leukocyte activation along with the expression of ad-
hesion molecules, and the production of various biolog-
ically active substances, including oxygen-free radicals,
arachidonic acid metabolites, platelet-activating factor,
nitric oxide, endothelins, and heat-shock proteins (HSPs)
[32, 33]. This proinflammatory cascade contributes to en-
dothelial injury of the renal microvascular bed [34], lead-
ing to the development of tubular dysfunction and ARF.
In addition, bacterial products can activate neutrophils
within an already injured kidney [35], and IL-8 acts to
recruit neutrophils to sites of inflammation [36]. Of note,
morphologic studies of acute tubular necrosis in humans
demonstrate a preponderance of neutrophils in vasa recta
and the interstitium, supporting a role for inflammation
in a condition that has often been thought to be nonin-
flammatory [37].
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Fig. 3. Schematic representation of the inflammatory response to sepsis and resulting kidney injury. (Modified from [205]; reprinted with permission.
Jaber BL et al: Blood Purif 22: 101–111, 2004). Abbreviations are: GFR, glomerular filtration rate; NAG, N-acetyl-b-D-glucosaminidase; KIM,
kidney injury molecule 1.
Ischemic and nephrotoxic injury in ARF
Although systemic or renal hemodynamic insults
are important in the pathogenesis of ARF, increasing
evidence supports an important role for inflammatory
mechanisms in the pathogenesis of ARF following both
ischemic [34] and nephrotoxic [38, 39] injury.
In a mice model of whole body ischemia, ARF is char-
acterized by inflammation with increased renal myeloper-
oxidase (MPO) levels and increased gene expression of
intercellular adhesion molecule-1 (ICAM-1) and IL-6
[40]. This inflammatory response as well as the develop-
ment of ARF is partly reduced in T-cell–deficient mice
[40], arguing for the importance of these cells in the
pathogenesis of ARF following ischemia/reperfusion in-
jury.
In a mouse model of cisplatin nephrotoxicity, ARF
is characterized by the activation of proinflammatory
cytokines (TNF-a and IL-1b mRNA) and chemokines
[monocyte chemotactic peptide-1 (MCP-1) mRNA], and
TNF-a urinary levels are increased [39]. The use of pen-
toxifylline, an inhibitor of TNF-a production, or a TNF-a
monoclonal antibody blunts cisplatin-induced increases
in TNF-a and IL-1b mRNA and reduces TNF-a urinary
levels. In addition, TNF-a inhibitors ameliorate cisplatin-
induced renal dysfunction and reduce structural damage.
Similarly, TNF-a–deficient mice are resistant to cisplatin
nephrotoxicity [39]. Overall, these data suggest that TNF-
a plays a central role in these responses [39].
Chemokines, including MCP-1 and IL-8, also play
a prominent role in the acute inflammatory response
in several models of ARF. Indeed, following ischemia/
reperfusion injury, kidney MCP-1 mRNA is increased
and correlates with the extent of mononuclear infiltrate
[41]. Finally, a kidney that is already primed with ac-
tivated inflammatory cells may be further affected by
the immunologic activation induced by the contact of
blood with poorly biocompatible dialysis membranes
[42].
With a growing body of evidence that there is increased
expression of proinflammatory cytokines in experimental
models of ARF, the role of anti-inflammatory strategies in
limiting tissue injury is emerging. For instance, the exoge-
nous administration of IL-10 inhibits TNF-a and ICAM-
1 mRNA expression in mice kidneys following ischemic
and nephrotoxic injury [38], and antibody to ICAM-1
protects the kidney against ischemic and nephrotoxic in-
jury [43, 44]. The administration of IL-10 also inhibits
macrophage-mediated injury in experimental glomeru-
lonephritis by inhibiting MCP-1, IL-1b , and ICAM-1
expression [45, 46].
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In humans, urinary cytokine levels correlate with uri-
nary markers of tubular dysfunction. Indeed, following
surgery with cardiopulmonary bypass (CPB), changes
in plasma and urinary cytokine homeostasis correlate
with urinary N-acetyl-b-D-glucosaminidase (NAG) level,
a biomarker of renal proximal tubular dysfunction [47,
48]. Whether urinary cytokines in humans are due to
filtration by the glomerulus or production in situ is not
clear. They may be involved in the pathobiology of ARF,
through paracrine effects. While the role of urinary cy-
tokines and other biomarkers of kidney injury remain
unknown, a recent study demonstrated the detection
of the soluble form of human kidney injury molecule-1
(KIM-1) in the urine of patients with biopsy-proven acute
tubular necrosis [49]. This transmembrane protein is ex-
pressed by the human renal proximal tubule, and has been
proposed as a useful biomarker for renal proximal tubule
injury, to facilitate the early diagnosis of ARF [34, 50].
In humans, plasma cytokine levels have been corre-
lated with the risk of ARF and adverse outcomes. Both
plasma IL-6 and IL-10 levels have been shown to differen-
tiate surviving from nonsurviving patients with ARF [51].
Furthermore, among patients with septic shock, elevated
serum levels of sTNF-R (forms I and II) were found to
be independent predictors for the development of ARF
and mortality [52]. In another study of septic patients, an
elevated plasma IL-6 to IL-10 ratio was associated with a
higher risk of multiple organ failure, suggesting that IL-10
deficiency may contribute to organ dysfunction in sepsis
[53].
Oxidative stress in ARF
Under normal physiologic conditions, a homeostatic
balance exists between the formation of ROS and their re-
moval by endogenous antioxidant compounds [54], which
reside in the intracellular space, the cellular membrane,
and the extracellular space.
The reduced form of nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidases are membrane-
associated enzymes that catalyze the production of
superoxide and they are highly expressed in neutrophils
and endothelial cells. [55]. NADPH oxidase has several
subunits, including gp91phox and p22phox, which are
electron-transfer proteins. These electron-transfer pro-
teins are predominantly intracellular in endothelial cells,
and extracellular in neutrophils [56]. This may explain
cell-specific differences in the function of the two en-
zymes. In sepsis and possibly ARF, there are several
potential sources of ROS, including the mitochondrial
respiratory electron transport chain, xanthine oxidase
activation as a result of ischemia/reperfusion and
neutrophil-associated respiratory burst via the activation
of membrane-bound NADPH oxidase [57].
MPO is released by activated neutrophils and mono-
cytes and takes part in primary host defenses by catalyz-
ing the production of hypochlorous acid, a potent oxidant
(Fig. 4). In addition to its antimicrobial activity, MPO
has been involved in a broad range of noninfectious dis-
eases, including ischemia/reperfusion injury, vasculitis,
atherosclerosis, cancer, and neurodegenerative disorders
[58].
In human cells, glutathione and the glutathione per-
oxidases (GPX) constitute the principal intracellular
antioxidant defense system [59]. There are at least four
different glutathione peroxidases, all of which contain se-
lenocysteine at their active sites [60]. Glutathione peroxi-
dase 1 (GPX1), the ubiquitous intracellular form and key
antioxidant enzyme within most cells, uses glutathione
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(GSH) to reduce hydrogen peroxide to water and lipid
peroxides to their respective alcohols [61], and it also re-
duces peroxynitrite [62]. Whereas GPX1 is particularly
abundant in the kidney, GPX2 is expressed primarily in
gastrointestinal tissues and GPX3 is extracellular and is
present mainly in the plasma. GPX4 is detected in most
tissues both in the cytosol and within membranes and has
the ability to reduce peroxidized phospholipids in cellular
membranes [63].
Superoxide dismutase (SOD) converts superoxide
anion to hydrogen peroxide and is represented by
three different ubiquitously expressed enzymes: cytosolic
copper- and zinc-containing SOD (SOD1), mitochondrial
manganese-containing SOD (SOD2), and extracellular
SOD (SOD3). Extracellular SOD is most active in the
vessel wall and has been shown to regulate the avail-
ability of nitric oxide by scavenging superoxide anion
[63, 64].
Although b-carotene, lycopene, and coenzyme Q have
all been implicated as cell membrane antioxidants, fat-
soluble vitamin E or a-tocopherol is by far the most
important free radical quencher, residing in the hy-
drophobic inner layer of membranes [57].
Finally, an additional line of extracellular antioxidant
compounds handles the extrusion of ROS into the ex-
tracellular space that can occur, for example, follow-
ing neutrophil activation. Indeed, metal-binding plasma
proteins, including lactoferrin and serum albumin, via
oxidizable thiol groups, which permit free radical scav-
enging, are valuable circulating antioxidants. Other im-
portant circulating antioxidants include vitamin C, uric
acid, and bilirubin [57].
Oxidative stress occurs when a balance is disrupted
by excessive production of ROS, including superoxide,
hydrogen peroxide, and hydroxyl radicals, and/or by in-
adequate antioxidant defenses [57], including suboptimal
levels of SOD, catalase, GPX, vitamins C and E, and re-
duced GSH (Fig. 4).
Both of these imbalances may occur in ARF. Indeed, in
recent years, considerable evidence has incriminated free
oxygen radicals and ROS in the pathogenesis of ischemic
and nephrotoxic ARF [65]. Experimental studies indicate
that deprivation of antioxidant defenses aggravates renal
injury [65]. Strategies to enhance endogenous antioxi-
dant defenses can attenuate renal injury induced by is-
chemic or nephrotoxic insults [65, 66]. These observations
have been supported by data from clinical observational
studies indicating depressed antioxidant defenses and in-
creased oxidative stress in critically ill patients with mul-
tiple organ failure, including ARF [67–69]. Deficiencies
of water-soluble vitamins and trace elements may also oc-
cur in patients with ARF undergoing renal replacement
therapy [69, 70], which may further compromise antioxi-
dant defenses. Finally, blood-membrane interactions and
neutrophil activation during dialysis may lead to the in-
tradialytic release of MPO and generation of ROS, which
further exacerbate oxidative stress [69]. This may be an
additional source of tissue injury as MPO activity is al-
ready enhanced in the renal parenchyma, following is-
chemia/reperfusion injury, reflecting on the recruitment
of activated neutrophils to sites of injury [71].
The use of N-acetyl cysteine (NAC) to prevent ARF
has recently emerged. This antioxidant acts primarily by
scavenging oxygen free radicals, mainly hydroxyl radicals.
This effect is most pronounced in the intracellular space
where it also helps restore reduced glutathione stores. In
humans, NAC has been shown to be beneficial in prevent-
ing contrast-induced nephropathy [72]. In experimental
models of ischemic ARF, NAC ameliorates renal vaso-
constriction, in part through prostaglandins and nitric ox-
ide [73, 74].
Nitric oxide metabolism in ARF
Nitric oxide is an important signaling molecule that
is generated from L-arginine by the action of nitric ox-
ide synthase (NOS), and has a half-life of only a few
seconds in vivo. However, it is soluble in both aqueous
and lipid media, and therefore, readily diffuses through
the cytoplasm and plasma membranes. In the vascula-
ture, nitric oxide stimulates the intracellular production
of cyclic guanosine monophosphate (cGMP), resulting in
smooth muscle relaxation and vasodilatation. In the ex-
tracellular milieu, nitric oxide reacts with oxygen and wa-
ter to form nitrates and nitrites, two harmless compounds.
Nitric oxide toxicity is linked to its ability to combine with
superoxide anions to form peroxynitrite, an oxidizing free
radical that can cause DNA fragmentation and lipid oxi-
dation. In the mitochondria, peroxynitrite acts on the res-
piratory chain complex and manganese-containing SOD,
to generate superoxide anions and hydrogen peroxide,
respectively.
In ischemia/reperfusion injury of the kidney, nitric ox-
ide is produced to a greater degree by tubular and inter-
stitial cells rather than the endothelium. In addition to
its role as a strong vasodilator, nitric oxide inhibits pro-
duction of vasoconstrictors and reduces inflammation by
neutralizing ROS [75]. Studies have found that nitric ox-
ide derived from inducible NOS (iNOS) contributes to
the preconditioning effect in the kidney [76]. Although
nitric oxide is not currently used as a therapy for renal
injury [77], there is evidence in humans that the use of
L-arginine, the substrate for iNOS-dependent nitric ox-
ide generation, reduces kidney injury [78].
Summary
In summary, although animal and human studies have
incriminated cytokines, chemokines, ROS, and nitric ox-
ide in the pathophysiology ARF, the role of susceptibility
genetic factors, which may influence the above mentioned
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Table 1. Selected list of polymorphism of immune response genes in humans
Polymorphism Gene expression
Gene Site Class Position or function Reference
Cytokines
TNF-a Promoter SNS (G to A) −238 Affected [80]
TNF-a Promoter SNS (G to A) −308 Affected [82–85]
TNF-b (LT-a) Intron SNS (G to A) +250 (intron 1) Affecteda [87]
TNF-b (LT-a) Intron SNS (G to A) +1069 (intron 1) Affecteda [86]
IL-1a Promoter SNS (C to T) −889 Affected [104]
IL-1a Intron 46-bpVNTR Intron 6 Unknown [206]
IL-1b Exon SNS (C to T) +3953 (exon 5) Affected [207]
IL-1b Promoter SNS (C to T) −511 Affected [105]
IL-1Ra Intron 86-bp VNTR Intron 2 Affected [111]
IL-6 Promoter SNS (G to C) −174 Affected [120, 122, 124]
IL-6 Promoter SNS (G to C) −572 Affected [121]
IL-10 Promoter SNS (G to A) −1082 Affected [132, 133]
IL-10 Promoter SNS (C to T) −819 Affected [80, 133]
IL-10 Promoter SNS (C to A) −592 Affected [80]
Chemokines
IL-8 Promoter SNS (A to T) −251 Affected [140, 141]
IL-8 3′UTR SNS (G to A) +2767 Affected [142, 143]
IL-8 Promoter SNS (C to T) −845 Affected [144]
MCP-1 Promoter SNS (G to A) −2518 Affected [145, 146]
Toll-like receptors (TLR)
TLR2 Exon SNS (C to T) +2029 Affected [208]
TLR2 Exon SNS (G to A) +2251 Affected [155]
TLR4 Exon SNS (A to G) +896 Affected [152]
Heat shock proteins (HSP)
HSP70-2 Exon SNS (G to A) +1267 Affected [159]
HSP70-2 Exon SNS (G to A) +1538 Unknown [160]
HSP70-Hom Exon SNS (C to T) +2437 Unknown [160]
Oxidant stress-related enzymes
HO-1 Promoter MSR (GT)n −263, −185 Affected [172, 173]
NADPH oxidase p22phox Exon SNS (C to T) +242 (exon 4) Affected [178]
NADPH oxidase p22phox 3′UTR SNS (A to G) +640 Unknown [178]
MPO Promoter SNS (G to A) −463 Affected [186, 187]
SOD3 Exon (C to G) +637 Affected [188]
Catalase Promoter SNS (C to T) −262 Affected [189]
GPX1 Exon MSR (GCG)n Exon 1 Unaffected [190]
GPX1 Exon SNS (C to T) +593 Unaffected [192]
GST M1 Exonb — — Affected [194, 195]
iNOS Promoter SNS (C to T) −1173 Affected [198]
Abbreviations are: SNS, single nucleotide substitution; VNTR, variable number of tandem repeats; MSR, microsatellite repeats; UTR, untranslated region; HSP,
heat shock protein; MPO, myeloperoxidase; SOD, superoxide dismutase; GPX, glutathione peroxidase; GST, glutathione-S transferase; iNOS, inducible nitric oxide
synthase; TNF, tumor necrosis factor; IL, interleukin; HO, heme oxygenase; NADPH, nicotinamide adenine dinucleotide phosphate.
a TNF-a production is affected.
b Gene deletion prevalent in up to 50% of humans.
specific gene activation pathways, and consequently, both
the development and severity of ARF following ischemic
or nephrotoxic injury, has remained largely unexplored.
Polymorphisms of selected immune response genes are
reviewed in the next section, with special emphasis on
those that have been associated with an altered rate of
gene expression. Associations between these polymor-
phisms and acute inflammatory states are summarized,
and implications in the field of ARF are hypothesized.
CANDIDATE GENES ALTERING THE
INTENSITY OF THE INFLAMMATORY
RESPONSE
The study of polymorphism of immune response genes
in human disease may enhance the understanding of the
cause and pathology of disease, identify potential mark-
ers of susceptibility, severity and clinical outcomes, iden-
tify potential markers for responders vs. nonresponders
in therapeutic trials, identify targets for therapeutic inter-
vention, and identify novel or improve existing strategies
to prevent disease [7, 8].
Host immune responses strongly correlate with the
severity and outcome of acute inflammatory and infec-
tious states, and the extent of the inflammatory responses
is in part genetically determined. In recent years, the
study of polymorphism of immune response genes, in-
cluding cytokines and other immune modulators, has be-
come the subject of intense interest, as these genetic
markers may be potential determinants of susceptibil-
ity to or severity of acute illnesses. Polymorphisms of
key immune regulatory molecules are reviewed (Tables 1
and 2).
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Table 2. Positive associations between polymorphism of immune response genes and acute infectious and inflammatory disorders
Gene Polymorphic allele Acute illness Reference
Cytokines
TNF-a −308 A-allele (TNFa2) Sepsis/septic shock [90–92, 97, 98]
TNF-a −308 A-allele (TNFa2) Meningococcal disease [94]
TNF-a −308 A-allele (TNFa2) Cerebral malaria [95]
TNF-a −308 A-allele (TNFa2) Mucocutaneous leishmaniasis [96]
TNF-a −308 A-allele (TNFa2) Rate of body temperature normalization following cardiopulmonary bypass [102]
TNF-a −308 A-allele (TNFa2) Neonatal acute renal failure [130]
TNF-a −308 A-allele (TNFa2) Severe acute kidney-pancreas transplant rejection episodes [135]
TNF-a −308 A-allele (TNFa2) Increased risk of death in dialysis-requiring acute renal failure [103]
TNF-a −238 A-allele Malarial anemia [209]
TNF-ba +250 AA genotype Septic shock in community-acquired pneumonia [93, 163]
TNF-b +250 G-allele Prolonged mechanical ventilation following cardiopulmonary bypass [99]
TNF-b +1069 (NcO1) allele 2/2 Septic shock following acute biliary pancreatitis [210]
TNF-b +1069 (NcO1) allele 2/2 Higher circulating TNF-a levels following cardiopulmonary bypass [100]
TNF-b +1069 (NcO1) allele 2/2 Increased mortality in severe sepsis [97]
TNF-b +1069 (NcO1) allele 2/2 Susceptibility to severe posttraumatic sepsis [98]
IL-1a −889 TT genotype Osteomyelitis [211]
IL-1b +3953 TT genotype Osteomyelitis [211]
IL-1b −511 allele 2/2 Febrile seizure in children [106]
IL-1b +3953 allele 2 Increased risk of ESRD in PR3-ANCA vasculitis [118]
IL-1b −511 allele 1/2 Survival in meningococcal disease [212]
IL-1Ra 86 bp VNTR (allele 2) Susceptibility to sepsis [113, 114]
IL-1Ra 86 bp VNTR (allele 2) Reduced Mantoux response to purified protein derivative of Mycobacterium
tuberculosis
[115]
IL-1Ra 86 bp VNTR (allele 2) Increased risk of ESRD in PR3-ANCA vasculitis [118]
IL-1Ra 86 bp VNTR (allele 2) Severity of Henoch-Scho¨nlein purpura-associated nephritis [116]
IL-1Ra 86 bp VNTR (allele 2) High soluble endothelial activation (von Willebrand factor and E-selectin)
markers in acute coronary syndromes
[117]
IL-6 −174 GG genotype Improved survival in sepsis [125]
IL-6 −174 C-allele Neonatal acute renal failure [130]
IL-6 −572 C-allele Higher serum C-reactive protein level [121]
IL-10 −1082 GA genotype Meningococcal disease [134]
IL-10 −1082 G-allele Severity of illness in community-acquired pneumonia [126]
IL-10 −1082 G-allele Severe acute kidney-pancreas transplant rejection episodes [135]
IL-10 −1082 GA genotype Susceptibility to pulmonary tuberculosis [213]
IL-10 −1082 G-allele Decreased risk of death in dialysis-requiring acute renal failure [103]
IL-10 −592 A-allele Increased mortality in sepsis [137]
IL-10 −592 AA genotype Decreased risk of acute GVHD and death [214]
Chemokines
IL-8 +2767 A-allele Henoch-Scho¨nlein purpura-associated nephritis [143]
IL-8 −251 A-allele Enteroaggregative Escherichia coli diarrhea [140]
IL-8 −251 A-allele Respiratory syncitial virus bronchiolitis [141]
IL-8 −845 C-allele Severity of lupus nephritis [144]
MCP-1 −2518 G-allele Premature kidney graft failure [147]
Toll-like receptors (TLR)
TLR2 Arg753Gln Gram-positive bacterial sepsis [155]
TLR2 Arg677Trp Susceptibility to lepromatous leprosy [157]
TLR4 Asp299Gly, Thr399Ile Gram-negative bacterial sepsis [154]
TLR4 Asp299Gly Sepsis and septic shock [153, 156]
Heat shock proteins (HSP)
HSP70-2 +1267 GG genotype Neonatal acute renal failure [159]
HSP70-2 +1267 AA genotype Increased risk of septic shock [163]
HSP70-Hom +1538 CT genotype Multiple organ failure following trauma [160]
Oxidant stress-related enzymes
HO-1 Long (GT)n repeats Increased susceptibility to coronary artery disease in diabetic patients [173]
HO-1 Long (GT)n repeats Increased risk of restenosis following PTCA [174]
HO-1 Long (GT)n repeats Increased risk for developing abdominal aortic aneurysm [175]
HO-1 Long (GT)n repeats Increased susceptibility to pulmonary emphysema in cigarette smokers [176]
NADPH oxidase +242 CC genotype Increased oxidized high-density lipoprotein cholesterol in type 2 diabetes [183]
p22phox mellitus
MPO −463 GG-genotype Increased prevalence of cardiovascular disease and higher circulating levels
of pentosidine in ESRD
[187]
GST GST M1-0 genotype Increased risk for lung cancer in heavy smokers [196]
GST GST M1-B allele carrier Decreased risk of delayed graft function [197]
iNOS −1173 T-allele carrier Decreased risk of malarial complications [198]
Abbreviations are: ESRD, end-stage renal disease; PR3-ANCA, proteinase 3 antineutrophilic cytoplasmic antibody; PTCA, percutaneous transluminal coronary
angioplasty; GVHD, graft versus host disease; GST, glutathione-S transferase; iNOS, inducible nitric oxide synthase; HO, heme oxygenase; MPO, myeloperoxidase; IL,
interleukin; TNF, tumor necrosis factor; NADPH, nicotinamide adenine dinucleotide phosphate.
aTNF-b is lymphotoxin alpha (LT-a).
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The TNF locus
The TNF-a and TNF-b [also known as lymphotoxin-a
(LT-a)] genes are located on the short arm of chromo-
some 6. Polymorphism within the 5′-flanking region of
the TNF-a gene at positions –238 (G to A) and –308 (G
to A) have been reported, and the –308 A-allele, also re-
ferred to as the TNF-a2 allele, has been associated with
high promoter activity [79–81]. Moreover, the TNF-a2
allele has been found to correlate with enhanced spon-
taneous and stimulated TNF-a production both in vitro
[82, 83] and in vivo [84, 85].
The gene coding for TNF-b (LT-a) is located near the
TNF-a gene. Single nucleotide polymorphism at position
+1069 (G to A) in the first intron of the gene has been
characterized [86]. The “A” variant is the TNF-b2 al-
lele whereas the less frequent “G” variant is known as
the TNF-b1 allele. The TNF-b1 allele is associated with
the presence of a digestion site for the DNA sequence-
specific restriction enzyme NcoI [87, 88]. This results
in a restriction fragment length polymorphism (RFLP).
Monocytes from TNF-b2 homozygous individuals pro-
duce significantly higher amount of IL-1b and TNF-a in
response to stimuli [87]. A recent study has demonstrated
strong linkage disequilibrium between TNF-a -308 (G to
A) promoter and TNF-b NcoI polymorphisms, whereby
heterozygosity for both TNF polymorphisms was asso-
ciated with an increased TNF-a response [89]. This find-
ing highlights the importance of linkage disequilibrium in
studies examining disease association with polymorphism
of individual immune response genes (see below).
Polymorphism in the TNF-a gene has been stud-
ied extensively and has been associated with adverse
clinical outcomes among patients suffering from sepsis
[90–92]. In one such study, the TNF-a high producer
genotype (TNF-a2 allele) was strongly associated with
an increased susceptibility to septic shock and mortal-
ity [90]. Furthermore, this TNF-a high producer geno-
type has been associated with increased morbidity and
mortality from several acute infectious diseases, includ-
ing community-acquired pneumonia [93], meningococcal
disease [94], malaria [95], and mucocutaneous leishmani-
asis [96]. Other studies have linked the TNF-b2 homozy-
gous carriage, also associated with a TNF-a high producer
genotype, to higher fatality among patients with severe
sepsis [97], and increased susceptibility to severe post-
traumatic sepsis [98].
A few studies have investigated the influence of poly-
morphisms in the TNF-a [99] and TNF-b [100] genes on
the expression of TNF-a in patients undergoing coro-
nary artery bypass graft (CABG) surgery with CPB. Some
have also associated the TNF-b +250 G-allele with pro-
longed mechanical ventilation [99, 101] and the TNF-a
–308 G-allele with a slower rate of body temperature nor-
malization following CABG surgery [102]. In one study
of patients with dialysis-requiring ARF, carriers of the
TNF-a −308 A-allele had higher TNF-a production by
endotoxin-stimulated whole blood leukocytes, a higher
APACHE II score and a higher mortality risk [103].
It is clear that these genetically determined differ-
ences related to TNF-a gene polymorphisms may influ-
ence variations in proinflammatory cytokine responses to
stressful stimuli. In patients with ARF, this may have im-
portant implications, as the extent of proinflammatory re-
sponses may dictate the severity of ARF and requirement
for dialysis, as well as overall morbidity and mortality.
The IL-1 gene family
IL-1 is an important mediator of inflammation and tis-
sue damage in multiple organs, both in experimental an-
imal models of disease and in human diseases. The IL-1
gene family consists of IL-1a, IL-1b , IL-1 receptors (I
and II), and IL-1Ra. The genes encoding the IL-1a, IL-
1b , and IL-1Ra proteins are located on the short arm of
chromosome 2, and the IL-1 receptor proteins on the long
arm of chromosome 2.
An analysis of the allelic polymorphism in the pro-
moter region of the IL-1a gene at position −889 revealed
that the TT genotype significantly increased the transcrip-
tional activity of the gene relative to the CC genotype,
with a slight increase of the IL-1a mRNA and plasma
protein levels [104].
A SNP has been identified within exon 5 of the IL-
1b gene at position +3953 (C to T), which has been as-
sociated with regulation of gene transcription [80]. An-
other polymorphism has also been described within the
5′-flanking promoter region of the gene at position –511
(C to T) [105]. The IL-1b −511 polymorphism has been
associated with febrile seizures in children [106], varia-
tion in CRP level [107], and severity of meningococcal
disease [105].
The IL-1Ra gene contains VNTR of 86 bp within in-
tron 2, giving rise to a penta-allelic minisatellite poly-
morphism. This is in linkage disequilibrium with IL-1Ra
polymorphism at position +2018 within exon 2 [108]. The
uncommon allele 2, which consists of two 86 bp repeats,
has been associated with increased IL-1b production in
vitro [109]. Some, but not all studies have also shown that
this allele is associated with increased IL-1Ra production
by human monocytes [110, 111]. Of note, a recent study
demonstrated that IL-1b bioactivity is under the genetic
control of IL-1Ra [112].
In several studies, the IL-1Ra polymorphic allele-2 has
been associated with increased susceptibility to sepsis
[113, 114], a reduced response to purified protein deriva-
tive of Mycobacterium tuberculosis (Mantoux test) [115],
and with severity of nephritis in Henoch Scho¨nlein pur-
pura [116]. Among patients with acute coronary syn-
dromes, the IL-1Ra allele-2 has also been associated
with higher soluble endothelial activation markers (von
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Willebrand factor and E-selectin) and the likelihood of
a troponin-positive status compared with noncarriage
[117].
Several studies have raised the question of whether
polymorphism of IL-1b and IL-1Ra, known as the IL-1
gene cluster, when examined in conjunction, may have a
role in the pathogenesis and/or severity of inflammatory
and infectious diseases, by influencing the ratio between
these two molecules. This altered ratio may lead to either
an attenuated or enhanced inflammatory reaction in situ
[118].
IL-6
Interleukin-6 is a pleiotropic cytokine with both pro-
and anti-inflammatory properties [119]. The IL-6 gene is
located on the long arm of chromosome 7. A polymor-
phism has been identified within the 5′-flanking region
of the IL-6 gene at position –174 (G to C) [120] and
–572 (G to C) [121]. Transient transfection experiments
using constructs containing either allele of the –174 5′-
flanking region polymorphism indicate that the C allele
results in suppression of IL-6 transcription in response to
endotoxin or IL-1b [120]. The presence of the C allele
has also been associated with lower serum levels of IL-6
in healthy subjects supporting the in vitro observation of
reduced promoter strength [120]. In contrast, carriers of
the wild-type IL-6 –174 G-allele have higher serum IL-6
levels [122].
The frequency of the IL-6 –174 C-allele has been
estimated at 40% in an Anglo-Saxon Caucasian pop-
ulation [120]. Limited data suggest, for instance, that
ethnic differences exist in regard to IL-6 genotype be-
tween Caucasian and African American populations in
the United States [123].
Studies linking the IL-6 –174 promoter region polymor-
phism to clinical outcomes in acute inflammatory states
have yielded conflicting results. In severely injured blunt
trauma patients, there was no association between the
IL-6 –174 promoter genotypes and ex vivo whole blood
IL-6 production levels after stimulation with endotoxin
[124]. In other studies, this polymorphism was not asso-
ciated with increased incidence of sepsis nor did it corre-
late with plasma IL-6 level [125]. This polymorphism also
failed to predict severity of illness in community-acquired
pneumonia [126] and episodes of acute renal allograft re-
jection [127].
These studies contrast with a few reports demonstrat-
ing an association between this polymorphism and acute
inflammatory disorders. In one study, there was a signifi-
cant association between the IL-6 –174 GG homozygous
genotype and improved survival in sepsis [125]. This was
independent of the systemic IL-6 response, arguing for
the role of other genetically linked polymorphisms that
might have been the underlying cause for this association.
The IL-6 –572 C-allele and −174 CC genotypes have cor-
related with perioperative IL-6 profiles among patients
undergoing CABG surgery [128]. This contrasts with one
study where among patients undergoing CABG surgery,
the IL-6 –174 GG homozygous genotype was associated
with higher acute phase levels of IL-6 and with longer
stays in the hospital and in the intensive care unit com-
pared with patients carrying the −174 C-allele [129].
The constellation of high TNF-a producer and low IL-6
producer genetic variants, which may lead to higher pro-
and lower anti-inflammatory capacities, has been associ-
ated with an increased risk for ARF in low-birth-weight
infants [130]. This is not inconceivable as high-dose IL-6
stimulates tubular regeneration in rat kidneys following
nephrotoxic injury [131], thus providing an additional ef-
fect by which IL-6 may influence the course of ARF.
In summary, the variability in association between IL-
6 gene polymorphism and acute inflammatory disorders
may stem from its known pro- and anti-inflammatory
properties and the high frequency of the wild-type in
the general population (i.e., the high IL-6 production
phenotype).
IL-10
The IL-10 gene is located on the long arm of chromo-
some 1. Studies have suggested that 70–80% of the vari-
ation in IL-10 production is genetically determined and
appears to be controlled at the transcriptional level [132].
The IL-10 5′-flanking region, which controls transcrip-
tion, is polymorphic with a single base pair substitution at
position −1082 (G to A) [133]. In vitro studies have iden-
tified three phenotypic secretion levels for IL-10 based
on allelic substitutions (G to A) at the −1082 position:
high or intermediate producers (−1082 G-allele carrier,
or genotypes GG for high and GA for intermediate pro-
ducers), and low producers (genotype AA) [80, 133].
These findings have been confirmed by transient trans-
fection studies of monocytic cell lines using constructs of
each haplotype [133]. Additional polymorphisms at posi-
tions –819 (C to T) and –592 (C to A) have been described
but have variably been linked to regulation of gene tran-
scription [80, 133]. Polymorphisms at these two sites are
in linkage disequilibrium.
IL-10 –1082 polymorphic alleles have been associ-
ated with susceptibility to meningococcal disease and ad-
verse clinical outcomes [134], and severity of illness in
community-acquired pneumonia [126]. An increased in-
cidence of acute kidney-pancreas transplant rejection has
been observed among organ recipients, as the IL-10 pro-
duction phenotype increases (low, intermediate, high),
but only among those with the TNF-a low producer phe-
notype [135]. The role of IL-10 as a costimulatory agent
for antigen-presenting cells is well known [136]. Such data
support the hypothesis that the extent of the alloimmune
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response following organ transplantation is in part ge-
netically determined, and that the IL-10 high producer
phenotype in this particular setting may be deleterious.
The IL-10 –592 A-allele has been associated with
higher mortality in sepsis [137]. In one study of patients
with dialysis-requiring ARF, the IL-10 –1082 G-allele car-
riage was associated with higher IL-10 production and
a lower risk of death after adjustment for APACHE II
score, multiple organ failure score, and sepsis [103].
Chemokines
IL-8 and MCP-1 are two potent neutrophil and mono-
cyte chemokines, respectively, which have been impli-
cated in the pathogenesis of inflammation in human
glomerulonephritis and acute renal allograft rejection
[138]. Several studies have attempted to link interpatient
variations in the extent of kidney injury to chemokine
gene polymorphism, as certain polymorphic alleles may
influence the level of chemokine expression in situ,
thereby affecting the severity of renal injury.
The IL-8 and MCP-1 genes are located on the short
arm of chromosome 4 and 17, respectively [139]. Polymor-
phism in the IL-8 promoter region at position –251 has
been associated with both enteroaggregative Escherichia
coli diarrhea [140] and respiratory syncitial virus bronchi-
olitis [141]. A polymorphism at position +2767 (G to A)
in the 3′-UTR region of the IL-8 gene has been shown to
contribute to its posttranscriptional regulation [142], and
an increased frequency of the +2767 A-allele has been
found among patients with Henoch Scho¨nlein purpura
who develop nephritis [143]. Finally, a novel polymor-
phism in the promoter region of the IL-8 gene at position
–845, found primarily in African Americans, has been as-
sociated with the severity of lupus nephritis [144].
A genetic polymorphism in the 5′-flanking region of the
MCP-1 gene at position −2518 has been shown to affect
MCP-1 expression [145]. Indeed, the MCP-1 –2518 G-
allele was associated with higher MCP-1 production lev-
els by human monocytes [145]. Furthermore, the MCP-
1 –2518 GG genotype has been associated with higher
plasma and urinary MCP-1 levels in patients with lupus
nephritis [146], and has been linked to a higher risk for
premature kidney graft failure [147].
Toll-like receptors
Toll-like receptors (TLR) are transmembrane proteins
that are key mediators of the innate immune response to
microbial pathogens. They are responsible for the recog-
nition and initiation of cell-mediated immune responses,
such as the release of inflammatory cytokines, phago-
cytosis, and the expression of costimulatory molecules
needed by antigen-presenting cells. Ten different sub-
types of TLRs (TLR 1 to 10) have been so far identified in
mammals, and these are responsible for the recognition
of separate classes of pathogens that have common spe-
cific molecular features, known as pathogen-associated
molecular patterns (PAMP).
TLR2 and TLR4 have received particular attention
because of their specificity for the recognition of pep-
tidoglycans, lipoteichoic acid, and other antigens specific
for gram-positive bacteria, and lipopolysaccharide (LPS)
and other bacterial glycolipids specific for gram-negative
bacteria [148], respectively. Genetic defects of TLR4 re-
ceptors in inbred mouse strains cause resistance to LPS
challenge [149]. This lack of an inflammatory response
to LPS has been reproduced with TLR4 knockout mice
[150]. On the other hand, overexpression of TLR4 in
transgenic mice results in an overwhelming inflammatory
response after LPS exposure [151].
Polymorphisms of both the TLR2 and TLR4 gene, af-
fecting bacterial antigen responsiveness, have recently
been identified in humans (Tables 1 and 2) [152]. These
polymorphic alleles have been linked to adverse clini-
cal outcomes in sepsis [153, 154], gram-positive [155] and
gram-negative [156] bacterial infections, as well as in my-
cobacterial infection [157].
Heat shock proteins
HSPs are highly conserved proteins that are expressed
in both physiologic and pathologic conditions. HSPs are
classified on the basis of molecular weight and the 70 kD
proteins referred as the HSP70 family represent the most
prominent group, and include constitutive HSP73 and
the stress inducible HSP72, HSP70-2, and HSP70-Hom
[158–160]. Members of the HSP70 family have been in-
criminated in the protection against cellular damage from
stressful stimuli by acting as chaperone molecules, bind-
ing to and preventing aggregation of denatured or abnor-
mal proteins, and facilitating the restoration of normal
protein function. Recent studies have shown that HSP70
proteins also act like cytokines and stimulate monocytes
to produce proinflammatory cytokines, including TNF-a,
IL-1b , and IL-6 [161]. The increased expression of HSP
attenuates experimental renal ischemic injury, and there-
fore, its modulation by pharmacologic maneuvers may be
critical in inflammatory conditions and organs prior to a
potential acute insult [162].
The genes encoding for HSP70 proteins are located
on chromosome 6. A SNP has been identified within the
exon region of the HSP70-2 gene at position +1267 (G
to A) [159] and +1538 (G to A) [160]. Another polymor-
phism has also been described within the codon region of
the HSP70-Hom gene at position +2437 (C to T) [160].
Neonates carrying the HSP70-2 (+1267) GG genotype,
which is associated with low inducibility of HSP70-2, are
at greater risk for developing ARF [159]. This contrasts
with a study of adults with community-acquired pneu-
monia where the HSP70-2 (+1267) AA genotype was
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associated with an increased risk of septic shock [163].
Finally, the HSP70-Hom (+1538) CT genotype has been
associated with multiple organ failure following trauma
[160].
Heme oxygenase-1
Heme oxygenase (HO) is the rate-limiting enzyme
in heme catabolism, which leads to the generation of
biliverdin, free iron, and carbon monoxide. Three mam-
malian HO isoforms have been identified, one of which,
HO-1, is a stress-responsive protein induced by various
oxidative agents. The kidney is one of the prominent
sites for intense oxidative processes in the body and is,
therefore, extremely vulnerable to free radical–mediated
injury [164]. Studies over the past decade indicate that
HO-1 is induced as a beneficial response in cells exposed
to a diverse array of toxic insults [165]. HO-1 overex-
pression using gene transfer protects rat livers as well
as rat kidney transplants from ischemia/reperfusion in-
jury [166]. Increased HO-1 expression is also cytoprotec-
tive in heme-mediated (e.g., rhabdomyolysis) as well as
nonheme-mediated (e.g., cisplatin-induced injury) mod-
els of ARF [165]. In addition, analyses of HO-1–null
mice as well as the first reported HO-1–deficient hu-
man have also emphasized the potent anti-inflammatory
properties of HO-1. Both mice and humans deficient in
HO-1 expression have a phenotype of an increased in-
flammatory state [167, 168]. Recent studies have focused
on the mechanisms by which HO-1 mediates its anti-
inflammatory effects. Carbon monoxide, one of the three
byproducts of heme catabolism by HO, mediates potent
anti-inflammatory effects through a mitogen-activated
protein kinase-dependent pathway [169]. Further, other
studies have shown that IL-10 induces expression of HO-
1 via a p38 mitogen-activated protein kinase-dependent
pathway [170]. The inhibition of HO-1 protein syn-
thesis or activity significantly reverses the inhibitory
effect of IL-10 on LPS-induced TNF-a production
[170]. In addition, IL-10-mediated protection against
LPS-induced septic shock is significantly attenuated by
cotreatment with the HO inhibitor, zinc protoporphyrin
[170]. These observations indicate that HO-1 is an im-
portant downstream effector of IL-10. The human HO-1
gene has been mapped to the long arm of chromosome
22 [171] and a highly length polymorphic (GT)n dinu-
cleotide repeat has been identified in the proximal pro-
moter region [172]. Transient transfection assays with
HO-1 promoter/luciferase fusion constructs carrying var-
ious lengths of (GT)n repeats indicate that longer (GT)n
repeats exhibit lower transcriptional activity [173]. Pa-
tients with type 2 diabetes mellitus carrying longer (GT)n
repeats have been shown to exhibit higher oxidative stress
and increased susceptibility to the development of coro-
nary artery disease [173]. Long (GT)n repeats have also
been associated with increased risk of restenosis after per-
cutaneous transluminal angioplasty [174], development
of abdominal aortic aneurysm [175], and increased sus-
ceptibility to pulmonary emphysema in cigarette smokers
[176]. The role of this HO-1 promoter (GT)n polymor-
phism in modulating susceptibility to or severity of ARF
has not been investigated. However, given the cytopro-
tective effects of HO-1 in experimental models of ARF,
it could potentially be an important genetic factor influ-
encing the pathobiology of acute renal injury.
Oxidant stress-related enzymes
Oxygen free radicals are important mediators of cel-
lular injury following organ ischemia and reperfusion
[177]. Although polymorphisms affecting key pro- and
anti-oxidant enzymes may alter the susceptibility to ox-
idative stress-mediated injury, the use of genetic epidemi-
ology for the study of oxidative stress-related genes has
received little attention in the setting of an acute illness
[63]. We will review a selected number of polymorphisms
of key oxidant stress–related genes, which may be func-
tionally relevant in human disease.
Given its importance in generating superoxide dur-
ing the respiratory burst of neutrophils, one might an-
ticipate that polymorphisms disrupting the function of
NADPH oxidase might alter oxidative stress-mediated
injury in acute inflammatory disorders. Polymorphisms
in the gene encoding the NADPH oxidase p22phox sub-
unit have been described. Among them, a single nu-
cleotide substitution (C to T) within exon 4 at position
+242, resulting in an amino acid substitution at position
72 (histidine to tyrosine), has been shown to modulate
enzyme activity through heme-binding affinity [178]. In
one study, the p22phox +242 CC genotype was associated
with higher basal and stimulated superoxide generation
by human endothelial cells, compared with the p22phox
+242 T allele [179]. Another single nucleotide substitu-
tion (A to G) at position +640 located in the 3′-UTR of
the p22phox gene has also been described, but is of un-
clear clinical significance [178]. More recent studies have
not supported a functional role for the A640G or C242T
polymorphisms either in determining endothelial func-
tion in patients with coronary artery disease [180] or hy-
percholesterolemia [181]. Studies on the influence of the
p22phox C242T polymorphism on circulating markers of
lipid peroxidation [i.e., malondialdehyde (MDA) levels]
have yielded conflicting results among patients with coro-
nary artery disease and type 2 diabetes mellitus [182, 183].
With respect to kidney disease, the NADPH oxi-
dase p22phox subunit is expressed by human glomerular
mesangial cells, and through the generation of super-
oxide, may contribute to glomerular injury. Unfortu-
nately, the p22phox C242T polymorphism has not been
associated with the severity of glomerulonephritis [184]
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or with the development of pre-eclampsia [185]. De-
spite these negative studies, the neutrophil-associated
NADPH oxidase system may be extremely important
in sepsis, whereby the respiratory burst during ischemia/
reperfusion injury may be in part genetically predeter-
mined. To date, no studies have attempted to link the
p22phox C242T polymorphism with the susceptibility to
or severity of acute organ injury in sepsis.
MPO is another neutrophil-associated enzyme, which
is an important mediator of cellular injury through the
generation of oxidants. Variations in the gene encoding
for MPO may influence protein expression, and there-
fore, may be linked to pathologic states through modula-
tion of oxidative activity. There is a well-described SNP
within the promoter region of the MPO gene at posi-
tion −463, consisting of a G to A substitution. The G
allele (in contrast to A allele) is associated with high tran-
scriptional activity [186]. In a recent study of patients
with chronic kidney failure, carriers of the MPO –463
GG-genotype (associated with higher MPO levels) had
a higher prevalence of cardiovascular disease and higher
circulating levels of pentosidine, a surrogate marker of
protein oxidation [187]. It remains to be seen whether
polymorphism of this critical neutrophil-associated en-
zyme is important in dictating severity of injury following
ischemia/reperfusion in ARF.
The SOD3 gene is located on the long arm of chromo-
some 4 and contains 3 exons. A single nucleotide substi-
tution (C to G) within exon 3 at position +637, resulting
in an amino acid substitution at position 213 (arginine
to glycine), has been associated with enhanced plasma
levels of extracellular SOD [188].
The catalase gene is located on the short arm of chro-
mosome 11 and contains 13 exons. A functional polymor-
phism in the human catalase promoter, consisting of a C
to T substitution at position –262, confers increased basal
expression in different cell types and higher enzyme ac-
tivity in red blood cells [189].
The GPX1 gene is located on the short arm of chromo-
some 3 and contains 2 exons. A microsatellite polymor-
phism involving a variable number of three nucleotides
repeats (GCG)n (poly-alanine) in exon 1 has been de-
scribed [190]. Three polymorphic alleles consisting of 5,
6, and 7 alanine repeats, however, have not been asso-
ciated with altered GPX1 activity [191]. Another poly-
morphism, consisting of a C to T substitution at position
+593, resulting in an amino acid change at position +197
(proline to leucine) has also been described, but is not
associated with altered GPX1 activity [192].
Glutathione S transferases (GSTs) are soluble enzymes
that play an important role in the detoxification of ox-
idative stress end-products including lipid and DNA hy-
droperoxides. There are at least four GST isoenzymes
(M, P, T, and Z) with many described polymorphic alle-
les [63]. The gene coding for GST M1, the most studied
compound, is located on the short arm of chromosome 1.
Three GST M1 alleles have been identified, GST M1-0,
GST M1-A, and GST M1-B [193]. Fifty percent of hu-
mans lack this enzyme (GST M1-0) [194], whereas the
GST M1-A and GST M1-B alleles differ at amino acid
residue 172, where lysine is replaced by asparagine, a
substitution that has no impact on the enzymatic activ-
ity [195]. Smokers who are GST M1 deficient (GST M1-
0) are at higher risk of developing lung cancer [196]. In
one study of genetic determinants of delayed graft func-
tion following kidney transplantation, patients receiving
a kidney from a donor who expressed GST M1-B either
alone or in combination with GST M1-A experienced
significantly lower rates of delayed graft function [197].
These promising data suggest that this antioxidant gene
may be protective against ischemia/reperfusion injury fol-
lowing organ transplantation, and may also be applicable
to ischemic and nephrotoxic ARF.
Nitric oxide synthase
In the kidney and the vasculature, nitric oxide is
produced by three major NOS isoforms: neuronal, en-
dothelial, and inducible NOS (nNOS, eNOS and iNOS),
respectively). Neuronal NOS and eNOS participate in the
homeostatic control of the vascular tone, the glomerular
microcirculation and other processes. In contrast, iNOS is
typically induced by proinflammatory stimuli to produce
large amounts of nitric oxide, which contributes to the
hemodynamic collapse of sepsis and inflammatory injury
responses of the glomerulus, vasculature, and the tubu-
lointerstitium.
A single nucleotide substitution (C to T) in the pro-
moter region of the iNOS isoform-2 (iNOS2) gene at
position −1173 has been shown to affect nitric oxide ex-
pression [198]. Indeed, the iNOS –1173 T-allele carrier
has been associated with increased fasting urinary and
plasma nitric oxide metabolite concentrations and with a
lower risk of malarial complications [198]. To date, there
are no known associations between iNOS polymorphism
and the development or severity of ARF.
LIMITATIONS OF GENETIC STUDIES
Polymorphism-association studies have traditionally
consisted of case-control studies, comparing the preva-
lence of a genetic marker in unrelated people with a given
disease to the prevalence in a control healthy popula-
tion. In general, such studies have been constrained by
small sample sizes, with chance accounting for the re-
sults, and therefore, they must be interpreted with cau-
tion, especially when biologic plausibility has not been
determined or is unknown. A better understanding of
genetically linked polymorphisms may be critically im-
portant, as the polymorphism of a particular gene may
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just be a marker for another, yet to be identified, disease-
causing sequence variant [199]. This more comprehen-
sive approach requires the use of linkage analyses and a
good understanding of neighboring candidate genes lo-
cated on the same chromosome. One such good example
is the cluster of the IL-1 gene family, with several genes
located in proximity on a single chromosome. Further-
more, most published studies describing the frequency of
cytokine gene polymorphisms in the general population
are biased due to a lack of consideration of ethnicity and
geographic boundary [200]. Indeed, certain genetic vari-
ants are infrequent in some but not other ethnic groups.
The HapMap Project is an international initiative, with
the long-term goal of determining the common patterns
of DNA sequence variation in the human genome. This
ambitious program plans to determine the genotypes of
one million or more sequence variants and their frequen-
cies in DNA samples from populations with ancestry from
parts of Africa, Asia, and Europe [201]. Through these
population-based genetic studies, the HapMap will allow
the discovery of sequence variants that affect common
disease across ethnicity and geographic boundary. This
endeavor will also facilitate the development of diagnos-
tic tools and targeted therapies.
Since genetic markers are present at birth and predate
onset of disease, confounding factors play a minor role
unless there is a strong interaction between these mark-
ers and an important acquired risk factor [200]. Finally,
survival bias is a real concern when genetic markers are
being evaluated as predictors of mortality. To circumvent
this important limitation, this would require the use of
case control studies with matching for age and follow-up
time, or more ideally, analytic prospective cohort studies
should be employed in an attempt to link polymorphic
genes to clinical outcomes over time [202].
Rosenthal and Schwartz [203] have proposed four cri-
teria that need to be fulfilled in establishing medically
useful links between genetic polymorphism and human
disease. These authors stressed that the genetic vari-
ant under study must cause a relevant alteration in the
function or level of the gene product. The number of
cases associating an allele with a particular phenotype
must be large enough to be convincing. The beneficial
and harmful phenotypes under study must have clear-cut
clinical differences and unequivocal allelic group assign-
ment. Finally, the plausibility of the hypothesis must be
convincing.
An important criterion that has also been proposed for
the study of genetic polymorphisms is the reproduction
of the results in different populations. Other issues to
consider when analyzing the results of SNP-association
studies pertain to the population characteristics, includ-
ing the choice of a control group (in case of case-control
studies), the prospective or retrospective design of the
study, the size, and admixture of the study population,
Table 3. The future of genetic studies in acute renal failure
Large prospective cohort studies
Careful phenotypic characterization
Analysis of genetic patterns and correlation with phenotypic patterns
Inclusion of genetic risk into an acute renal failure-risk algorithm
Use in risk quantification
Use in targeting of therapeutic strategies
“GeneChip” studies
the precise phenotypic characterization, and the effects
of confounders. Finally, the demonstration of the strength
of an association, the specificity of the effect, the presence
of a biologic gradient and gene-dose effect and the notion
of temporality all need to be considered.
POTENTIAL RELEVANCE OF GENE
POLYMORPHISM IN ARF
ARF is influenced by acquired risk factors such as an
exposure to a nephrotoxic drug, and arguably by genetic
risk factors that are present at birth. The pathobiology
of ARF suggests that products of many genes act con-
comitantly, culminating in a beneficial or deleterious bal-
ance of pro- and anti-inflammatory molecules, which in
turn, determines the extent of tissue injury. The number of
recognized gene polymorphisms is growing daily. There-
fore, future studies should focus on the investigation of
combinations of genetic markers. Some have proposed
that compilation of “genetic patterns” could be associ-
ated with different “clinical patterns” [88], such as for
instance, an increased susceptibility or resistance to ARF.
The future of genetic studies in ARF is summarized
in Table 3. In brief, genetic epidemiology studies may
help unravel the relative importance of genetic markers
in predicting the development of hospital-acquired ARF.
This would require large prospective cohort studies with
strong correlation between these genetic markers and the
early detection of urinary biomarkers of kidney injury, a
rise in serum creatinine level and dialysis requirement. In
the event of successful associations between these mark-
ers and outcomes, this would provide the basis for ad-
ditional studies where this genetic information could be
used to stratify patients who are at the highest risk of
developing ARF. More important, this knowledge may
have far reaching consequences and help identify target
patients in clinical trials undergoing high-risk procedures
who may benefit from immunomodulatory therapeutic
strategies, on the basis of their genotype profiles, with
the hope of preventing or attenuating kidney injury.
CONCLUSION
In summary, in vitro and animal studies have incrimi-
nated cytokines and other immunoregulatory molecules
as important mediators of kidney injury. The relative
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importance of genetic factors such as polymorphisms
involving immune response genes, in influencing sus-
ceptibility to ARF and adverse clinical outcomes, has
remained largely unexplored and merits full attention.
Based on the strength of associations observed in stud-
ies between gene polymorphisms and the susceptibility to
or severity of acute illness and adverse outcomes, we be-
lieve that some promising and emerging candidate genes
to study in ARF would include the TNF and IL-10 gene
[103, 204].
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